× |
|
INDIGOTINDISULFONATE SODIUM Drug Excipient Business Development Opportunity Report, 2024 |
$699.00 |
|
$699.00 |
× |
|
WEGOVY (semaglutide) Drug Profile, 2024 |
$699.00 |
|
$699.00 |
× |
|
ZEPOSIA (ozanimod hydrochloride) Drug Profile, 2024 |
$699.00 |
|
$699.00 |
× |
|
POTASSIUM CHLORIDE Drug Excipient Business Development Opportunity Report, 2024 |
$699.00 |
|
$699.00 |
× |
|
VYZULTA (latanoprostene bunod) Drug Profile, 2024 |
$699.00 |
|
$699.00 |
× |
|
XYWAV (calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate) Drug Profile, 2024 |
$699.00 |
|
$699.00 |
× |
|
VENCLEXTA (venetoclax) Drug Profile, 2024 |
$699.00 |
|
$699.00 |
× |
|
GLYCERIN Drug Excipient Business Development Opportunity Report, 2024 |
$699.00 |
|
$699.00 |
× |
|
ZYDELIG (idelalisib) Drug Profile, 2024 |
$699.00 |
|
$699.00 |
× |
|
CONTRAVE (bupropion hydrochloride; naltrexone hydrochloride) Drug Profile, 2024 |
$699.00 |
|
$699.00 |
|